-4.26%
-8.04%
-17.70%
-37.84%
-37.41%
1.24%
-45.41%
AI Spotlight on IONS
Company Description
Ionis Pharmaceuticals, Inc.discovers and develops RNA-targeted therapeutics in the United States.The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1.In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer.It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.was founded in 1989 and is based in Carlsbad, California.
Market Data
| Last Price | 31.9 |
| Change Percentage | -4.26% |
| Open | 32.55 |
| Previous Close | 33.32 |
| Market Cap ( Millions) | 5037 |
| Volume | 2360126 |
| Year High | 52.34 |
| Year Low | 31.4 |
| M A 50 | 35.23 |
| M A 200 | 40.86 |
Financial Ratios
| FCF Yield | -7.41% |
| Dividend Yield | 0.00% |
| ROE | -89.18% |
| Debt / Equity | 218.37% |
| Net Debt / EBIDTA | -440.18% |
| Price To Book | 7.16 |
| Price Earnings Ratio | -13.21 |
| Price To FCF | -13.49 |
| Price To sales | 6.27 |
| EV / EBITDA | -24.34 |
News
- Jan -15 - Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034
- Jan -13 - Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
- Jan -08 - Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
- Dec -23 - Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
- Dec -20 - Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
- Dec -20 - FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
- Dec -19 - TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
- Dec -19 - US FDA approves Ionis Pharma's genetic disorder drug
- Dec -11 - How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
- Nov -27 - Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
- Nov -18 - Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
- Nov -07 - Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
- Nov -07 - Ionis to present at upcoming investor conferences
- Nov -06 - Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
- Nov -06 - Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
- Nov -06 - Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
- Nov -06 - Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
- Nov -06 - Ionis reports third quarter 2024 financial results
- Nov -04 - Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Nov -04 - Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Human Therapeutic Medicines
Expected Growth : 10.43 %
What the company do ?
Human Therapeutic Medicines from Ionis Pharmaceuticals, Inc. are RNA-targeted medicines that modulate gene expression to treat various diseases, including neurological and metabolic disorders.
Why we expect these perspectives ?
Ionis Pharmaceuticals' Human Therapeutic Medicines segment growth of 10.43% is driven by increasing demand for Spinraza, a treatment for spinal muscular atrophy, and strong sales of Tegsedi, a treatment for polyneuropathy. Additionally, the company's pipeline of novel antisense medicines and collaborations with major pharmaceutical companies, such as Biogen and AstraZeneca, contribute to its growth momentum.
Ionis Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| SPINRAZA | A prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. |
| TEGSEDI | A prescription medicine used to treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |
| WAYLIVRA | A prescription medicine used to treat familial chylomicronemia syndrome (FCS) in adults. |
| VOLanesorsen | An investigational antisense medicine for the treatment of familial chylomicronemia syndrome (FCS). |
| AKCEA-APO(a)-LRx | An investigational antisense medicine for the treatment of high lipoprotein(a) levels. |
| AKCEA-ANGPTL3-LRx | An investigational antisense medicine for the treatment of certain cardiovascular diseases. |
Ionis Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Ionis Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the diseases they are targeting. However, their proprietary antisense technology provides a competitive advantage.
Bargaining Power Of Customers
Ionis Pharmaceuticals, Inc. has a low bargaining power of customers due to the specialized nature of their products and the lack of alternative treatment options for patients.
Bargaining Power Of Suppliers
Ionis Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment. However, the company's reliance on a few key suppliers for certain components may limit their negotiating power.
Threat Of New Entrants
Ionis Pharmaceuticals, Inc. has a low threat of new entrants due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development and regulatory approvals.
Intensity Of Rivalry
Ionis Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continually innovate and invest in research and development to stay ahead of competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 78.99% |
| Debt Cost | 4.74% |
| Equity Weight | 21.01% |
| Equity Cost | 5.99% |
| WACC | 5.00% |
| Leverage | 375.90% |
Ionis Pharmaceuticals, Inc. : Quality Control
Ionis Pharmaceuticals, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| CLDX | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
| RVMD | Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
Denali Therapeutics
A-Score
1-Year Total Return ->
🥉
Revolution Medicines
A-Score
1-Year Total Return ->
4
Amicus Therapeutics
A-Score
1-Year Total Return ->
5
Celldex Therapeutics
A-Score
1-Year Total Return ->
6
